HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, D. B. Articles by Kuo, L. C. Search for Related Content PubMed PubMed Citation Articles by Olsen, D. B. Articles by Kuo, L. C. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 34, 23699-23701, August 20, 1999

COMMUNICATION
Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors

From the Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486

Three high level, cross-resistant variants of the HIV-1 protease have been analyzed for their ability to bind four protease inhibitors approved by the Food and Drug Administration (saquinavir, ritonavir, indinavir, and nelfinavir) as AIDS therapeutics. The loss in binding energy (G_b) going from the wild-type enzyme to mutant enzymes ranges from 2.5 to 4.4 kcal/mol, 40-65% of which is attributed to amino acid substitutions away from the active site of the protease and not in direct contact with the inhibitor. The data suggest that non-active site changes are collectively a major contributor toward engendering resistance against the protease inhibitor and cannot be ignored when considering cross-resistance issues of drugs against the HIV-1 protease.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				Y.-T. Kim, H. Yoshida, M. Kojima, R. Kurita, W. Nishii, T. Muramatsu, H. Ito, S. J. Park, and K. Takahashi The Effects of Mutations in the Carboxyl-Terminal Region on the Catalytic Activity of Escherichia coli Signal Peptidase I J. Biochem., February 1, 2008; 143(2): 237 - 242. [Abstract] [Full Text] [PDF]

				C. Charpentier, D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors J. Virol., April 15, 2004; 78(8): 4234 - 4247. [Abstract] [Full Text] [PDF]

				V. Simon, N. Padte, D. Murray, J. Vanderhoeven, T. Wrin, N. Parkin, M. Di Mascio, and M. Markowitz Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection J. Virol., July 15, 2003; 77(14): 7736 - 7745. [Abstract] [Full Text] [PDF]

				R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]